Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from AstraZeneca, Eisai Inc., and Merck & Co., Inc.

Virtual Tumor Board®: Exploring the Practicalities of Gynecologic Cancer Management As New Options Emerge

Release Date: February 26, 2021
Expiration Date: February 26, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in gynecologic malignancies. In this educational program our panel of experts will consider case studies and apply recent data to real-world scenarios. This activity will serve as a comprehensive update for clinicians who treat a range of gynecologic cancers.

This educational activity is an archive of the live virtual symposium held on January 26, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Eisai Inc., and Merck & Co., Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, pathologists, surgical oncologists, and other clinicians involved in the management of patients with gynecologic cancers.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the rationale for molecular and genetic testing prior to targeted and immunotherapy agents in patients with gynecological cancers
  • Assess clinical trial data for targeted and immunotherapy agents, alone or in combination, in patients with gynecologic cancers across multiple settings
  • Outline strategies to monitor and manage toxicities associated with targeted and immunotherapy agents used in the treatment of gynecologic cancers
  • Apply evidence from landmark trials evaluating targeted and immune-based therapies to real-world-case scenarios of gynecological cancers in the maintenance and relapsed/refractory settings

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Ursula A. Matulonis, MD
Ursula A. Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Consultant: Merck & Co.

Robert L. Coleman, MD, FACOG, FACS
Robert L. Coleman, MD, FACOG, FACS
Gynecologic Oncologist and Chief Scientific Officer
US Oncology Research
The Woodlands, TX

Disclosures: Grant/Research Support: AstraZeneca, Clovis Oncology, Genmab/Seagen, ImmunoGen, Merck & Co.; Consultant: AstraZeneca, Clovis Oncology, Deciphera Pharmaceuticals, Genmab/Seagen, GlaxoSmithKline, Gradalis, ImmunoGen, Merck & Co., Toray.

Bradley J. Monk, MD, FACS, FACOG
Bradley J. Monk, MD, FACS, FACOG
Professor and Director, Division of Gynecologic Oncology
Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center
Professor on the Clinical Scholar Track
University of Arizona College of Medicine
Physician, Arizona Oncology (US Oncology Network)
Medical Director of Gynecologic Oncology Research, US Oncology
Co-Director, GOG Partners
Phoenix, AZ

Disclosures: Consultant: AbbVie, Agenus, Akesobio, Aravive, AstraZeneca, Clovis Oncology, Eisai, Genmab/Seagen, GOG Foundation, ImmunoGen, Iovance Biotherapeutics, Merck & Co., Mersana Therapeutics, Myriad Genetics, Pfizer, Puma Biotechnology, Roche/Genentech, Starton Therapeutics, Tesaro/GlaxoSmithKline, Vavotar Life Sciences, VBL Therapeutics; Speakers Bureau: AstraZeneca, Clovis Oncology, Eisai, Merck & Co., Roche/Genentech, Tesaro/GlaxoSmithKline.

Ritu Salani, MD, MBA
Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
University of California, Los Angeles
Los Angeles, CA

Disclosures: Consultant: GlaxoSmithKline, Merck & Co., Seagen.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By